Amid Sliding Revenue and Rising Costs, Bruker Cuts 5 Percent of Workforce; Reorg to Hit R&D | GenomeWeb

Following two successive quarters of declining revenues and swelling costs, Bruker Biosciences has eliminated approximately 60 positions, or 5 percent of its staff, via attrition, early retirement and lay-offs, the company announced last week.

“There was a creeping up of expenses,” said Michael Willett, a spokesman for Bruker. “We want to continue to fund R&D and this was a step to enhance profitability and to be profitable in general.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.